ARPO—(+19%/AH)—climbs on the COVID-19 bandwagon: https://finance.yahoo.com/news/aerpio-pharmaceuticals-inc-quantum-leap-203010639.html Why not? ARPO is a diabetes company, and T2D supposedly elevates the risk in COVID-19 infection. (I’m being facetious.)